N-[2-(1H-indol-3-yl)ethyl]-2-methyl-6-phenylthieno[2,3-d]pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[2-(1H-indol-3-yl)ethyl]-2-methyl-6-phenylthieno[2,3-d]pyrimidin-4-amine
• 化学式: C₂₃H₂₀N₄S
• 分子量: 384.5
• InChiKey: BDZSJWVTJFSUAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS
  申请人：Celularity Inc.

  公开号：EP3887364A1

  公开（公告）日：2021-10-06
• EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS
  申请人：Celularity Inc.

  公开号：EP3887508A1

  公开（公告）日：2021-10-06
• PLACENTAL DERIVED NATURAL KILLER CELLS FOR TREATMENT OF CORONAVIRUS INFECTIONS
  申请人：Celularity Inc.

  公开号：US20220000919A1

  公开（公告）日：2022-01-06

  Provided herein are methods of using populations of natural killer (NK) cells and/or ILC3 cells derived from a population of hematopoietic stem or progenitor cells in methods for treating a viral infection, e.g., a coronavirus infection.
• POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CD38 CHIMERIC ANTIGEN RECEPTOR
  申请人：Celularity Inc.

  公开号：US20220273716A1

  公开（公告）日：2022-09-01

  Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.
• POPULATIONS OF NATURAL KILLER CELLS FOR TREATING CANCERS
  申请人：CELULARITY INC.

  公开号：US20220265712A1

  公开（公告）日：2022-08-25

  Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of CYNK cells to the subject so as thereby to provide an effective treatment of the cancer in the subject. The CYNK cells can be placental-derived natural killer (NK) cells or placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and acute myeloid leukemia. The present invention also provides compositions comprising CYNK cells for the treatment of multiple myeloma and acute myeloid leukemia and methods of their use.